Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

ERα-Mediated Nuclear Sequestration of RSK2 Is Required for ER+ Breast Cancer Tumorigenesis.

Ludwik KA, McDonald OG, Brenin DR, Lannigan DA.

Cancer Res. 2018 Apr 15;78(8):2014-2025. doi: 10.1158/0008-5472.CAN-17-2063. Epub 2018 Jan 19.

2.

Stereoselective Synthesis and Evaluation of C6″-Substituted 5a-Carbasugar Analogues of SL0101 as Inhibitors of RSK1/2.

Li M, Li Y, Ludwik KA, Sandusky ZM, Lannigan DA, O'Doherty GA.

Org Lett. 2017 May 5;19(9):2410-2413. doi: 10.1021/acs.orglett.7b00945. Epub 2017 Apr 25.

PMID:
28441024
3.

Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.

Ludwik KA, Campbell JP, Li M, Li Y, Sandusky ZM, Pasic L, Sowder ME, Brenin DR, Pietenpol JA, O'Doherty GA, Lannigan DA.

Mol Cancer Ther. 2016 Nov;15(11):2598-2608. Epub 2016 Aug 15.

4.

Ribosomal S6 kinase (RSK) modulators: a patent review.

Ludwik KA, Lannigan DA.

Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. doi: 10.1080/13543776.2016.1212839. Epub 2016 Aug 1. Review.

PMID:
27410995
5.

Synthesis and Structure-Activity Relationship Study of 5a-Carbasugar Analogues of SL0101.

Li M, Li Y, Mrozowski RM, Sandusky ZM, Shan M, Song X, Wu B, Zhang Q, Lannigan DA, O'Doherty GA.

ACS Med Chem Lett. 2014 Nov 26;6(1):95-9. doi: 10.1021/ml5004525. eCollection 2015 Jan 8.

6.

De novo synthesis and biological evaluation of C6″-substituted C4″-amide analogues of SL0101.

Mrozowski RM, Sandusky ZM, Vemula R, Wu B, Zhang Q, Lannigan DA, O'Doherty GA.

Org Lett. 2014 Nov 21;16(22):5996-9. doi: 10.1021/ol503012k. Epub 2014 Nov 5.

7.

Improving the affinity of SL0101 for RSK using structure-based design.

Mrozowski RM, Vemula R, Wu B, Zhang Q, Schroeder BR, Hilinski MK, Clark DE, Hecht SM, O'Doherty GA, Lannigan DA.

ACS Med Chem Lett. 2012 Feb 14;4(2):175-179. Epub 2012 Dec 26.

8.

Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor.

Utepbergenov D, Derewenda U, Olekhnovich N, Szukalska G, Banerjee B, Hilinski MK, Lannigan DA, Stukenberg PT, Derewenda ZS.

Biochemistry. 2012 Aug 21;51(33):6499-510. doi: 10.1021/bi300620c. Epub 2012 Aug 6.

9.

Analogs of the RSK inhibitor SL0101: optimization of in vitro biological stability.

Hilinski MK, Mrozowski RM, Clark DE, Lannigan DA.

Bioorg Med Chem Lett. 2012 May 1;22(9):3244-7. doi: 10.1016/j.bmcl.2012.03.033. Epub 2012 Mar 13.

10.

Sustained activation of the HER1-ERK1/2-RSK signaling pathway controls myoepithelial cell fate in human mammary tissue.

Pasic L, Eisinger-Mathason TS, Velayudhan BT, Moskaluk CA, Brenin DR, Macara IG, Lannigan DA.

Genes Dev. 2011 Aug 1;25(15):1641-53. doi: 10.1101/gad.2025611.

11.

Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.

Andreani A, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Varoli L, Lannigan D, Smith J, Scudiero D, Kondapaka S, Shoemaker RH.

Eur J Med Chem. 2011 Sep;46(9):4311-23. doi: 10.1016/j.ejmech.2011.07.001. Epub 2011 Jul 8.

PMID:
21794960
12.

A chromatin-bound kinase, ERK8, protects genomic integrity by inhibiting HDM2-mediated degradation of the DNA clamp PCNA.

Groehler AL, Lannigan DA.

J Cell Biol. 2010 Aug 23;190(4):575-86. doi: 10.1083/jcb.201002124.

13.

RSK in tumorigenesis: connections to steroid signaling.

Eisinger-Mathason TS, Andrade J, Lannigan DA.

Steroids. 2010 Mar;75(3):191-202. doi: 10.1016/j.steroids.2009.12.010. Epub 2010 Jan 4. Review.

14.

RSK2 Binding Models Delineate Key Features for Activity.

Gussio R, Currens MJ, Scudiero DA, Smith JA, Lannigan DA, Shoemaker RH, Zaharevitz DW, Nguyen TL.

J Chem Pharm Res. 2010;2(5):587-598.

15.

RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility.

Larrea MD, Hong F, Wander SA, da Silva TG, Helfman D, Lannigan D, Smith JA, Slingerland JM.

Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9268-73. doi: 10.1073/pnas.0805057106. Epub 2009 May 22.

16.

Codependent functions of RSK2 and the apoptosis-promoting factor TIA-1 in stress granule assembly and cell survival.

Eisinger-Mathason TS, Andrade J, Groehler AL, Clark DE, Muratore-Schroeder TL, Pasic L, Smith JA, Shabanowitz J, Hunt DF, Macara IG, Lannigan DA.

Mol Cell. 2008 Sep 5;31(5):722-36. doi: 10.1016/j.molcel.2008.06.025.

17.

RNA suppression of ERK2 leads to collapse of mitochondrial membrane potential with acute oxidative stress in human lens epithelial cells.

Flynn JM, Lannigan DA, Clark DE, Garner MH, Cammarata PR.

Am J Physiol Endocrinol Metab. 2008 Mar;294(3):E589-99. doi: 10.1152/ajpendo.00705.2007. Epub 2008 Jan 2.

18.

Structural basis for the activity of the RSK-specific inhibitor, SL0101.

Smith JA, Maloney DJ, Hecht SM, Lannigan DA.

Bioorg Med Chem. 2007 Jul 15;15(14):5018-34. Epub 2007 Apr 2.

PMID:
17512736
19.

Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore.

Nguyen TL, Gussio R, Smith JA, Lannigan DA, Hecht SM, Scudiero DA, Shoemaker RH, Zaharevitz DW.

Bioorg Med Chem. 2006 Sep 1;14(17):6097-105. Epub 2006 May 24.

PMID:
16723234
20.

Influence of rhamnose substituents on the potency of SL0101, an inhibitor of the Ser/Thr kinase, RSK.

Smith JA, Maloney DJ, Clark DE, Xu Y, Hecht SM, Lannigan DA.

Bioorg Med Chem. 2006 Sep 1;14(17):6034-42. Epub 2006 May 24.

PMID:
16723233
21.

Three acetylated flavonol glycosides from Forsteronia refracta that specifically inhibit p90 RSK.

Xu YM, Smith JA, Lannigan DA, Hecht SM.

Bioorg Med Chem. 2006 Jun 1;14(11):3974-7. Epub 2006 Mar 9.

PMID:
16524738
22.

Novel biosensors for the detection of estrogen receptor ligands.

De S, Macara IG, Lannigan DA.

J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):235-44.

PMID:
15985367
23.

The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation.

Clark DE, Errington TM, Smith JA, Frierson HF Jr, Weber MJ, Lannigan DA.

Cancer Res. 2005 Apr 15;65(8):3108-16.

24.

Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.

Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA.

Cancer Res. 2005 Feb 1;65(3):1027-34.

25.

Extracellular signal-regulated kinase 7, a regulator of hormone-dependent estrogen receptor destruction.

Henrich LM, Smith JA, Kitt D, Errington TM, Nguyen B, Traish AM, Lannigan DA.

Mol Cell Biol. 2003 Sep;23(17):5979-88.

26.

Estrogen receptor phosphorylation.

Lannigan DA.

Steroids. 2003 Jan;68(1):1-9. Review.

PMID:
12475718
27.

Rsk2 allosterically activates estrogen receptor alpha by docking to the hormone-binding domain.

Clark DE, Poteet-Smith CE, Smith JA, Lannigan DA.

EMBO J. 2001 Jul 2;20(13):3484-94.

28.
29.

Generation of constitutively active p90 ribosomal S6 kinase in vivo. Implications for the mitogen-activated protein kinase-activated protein kinase family.

Poteet-Smith CE, Smith JA, Lannigan DA, Freed TA, Sturgill TW.

J Biol Chem. 1999 Aug 6;274(32):22135-8. Erratum in: J Biol Chem 1999 Nov 26;274(48):34506.

30.
31.
32.

pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167.

Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA.

Mol Cell Biol. 1998 Apr;18(4):1978-84.

33.
34.

Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor.

Joel PB, Traish AM, Lannigan DA.

Mol Endocrinol. 1995 Aug;9(8):1041-52.

PMID:
7476978
35.

Estrogen-responsive elements contain non-B DNA.

Lannigan DA, Koszewski NJ, Notides AC.

Mol Cell Endocrinol. 1993 Jul;94(1):47-54.

PMID:
8375575
36.

Analysis of estrogen receptor interaction with tertiary-structured estrogen responsive elements.

Lannigan DA, Tomashek JJ, Obourn JD, Notides AC.

Biochem Pharmacol. 1993 May 5;45(9):1921-8.

PMID:
8494551
37.

A novel mechanism for eukaryotic gene expression. The involvement of DNA tertiary structure in estrogen receptor recognition of its target nucleotide sequence.

Lannigan DA, Notides AC.

Biochem Pharmacol. 1990 Dec 15;40(12):2579-85. Review. No abstract available.

PMID:
2260983
38.

Estrogen regulation of transcription.

Lannigan DA, Notides AC.

Prog Clin Biol Res. 1990;322:187-97. Review. No abstract available.

PMID:
2406732
39.

Estrogen receptor selectively binds the "coding strand" of an estrogen responsive element.

Lannigan DA, Notides AC.

Proc Natl Acad Sci U S A. 1989 Feb;86(3):863-7.

40.

Phenamil, an amiloride analogue, inhibits differentiation of Friend murine erythroleukemic cells.

Lannigan DA, Bennington JB, Cragoe EJ Jr, Knauf PA.

Am J Physiol. 1988 Jan;254(1 Pt 1):C122-9.

PMID:
3422134
41.
42.

Supplemental Content

Loading ...
Support Center